Farhad Sahebkar

588 total citations
14 papers, 195 citations indexed

About

Farhad Sahebkar is a scholar working on Pharmacology, Molecular Biology and Oncology. According to data from OpenAlex, Farhad Sahebkar has authored 14 papers receiving a total of 195 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pharmacology, 6 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Farhad Sahebkar's work include Cannabis and Cannabinoid Research (9 papers), Polyamine Metabolism and Applications (5 papers) and Polyomavirus and related diseases (4 papers). Farhad Sahebkar is often cited by papers focused on Cannabis and Cannabinoid Research (9 papers), Polyamine Metabolism and Applications (5 papers) and Polyomavirus and related diseases (4 papers). Farhad Sahebkar collaborates with scholars based in United States, United Kingdom and Australia. Farhad Sahebkar's co-authors include Lesley Taylor, Gilmour Morrison, Bola Tayo, Elizabeth A. Thiele, James W. Wheless, Patrick Kwan, Steven Sparagana, E. Martina Bebin, Francis Filloux and Daniel Checketts and has published in prestigious journals such as Neurology, Epilepsia and Clinical Pharmacokinetics.

In The Last Decade

Farhad Sahebkar

14 papers receiving 192 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Farhad Sahebkar United States 7 126 82 46 34 33 14 195
Marta Żołnowska United States 7 159 1.3× 225 2.7× 123 2.7× 19 0.6× 100 3.0× 11 365
Richard J. Huntsman Canada 10 86 0.7× 86 1.0× 52 1.1× 10 0.3× 52 1.6× 20 276
Chloe Verducci United States 6 100 0.8× 178 2.2× 89 1.9× 7 0.2× 89 2.7× 9 266
Henry Blanton United States 8 151 1.2× 22 0.3× 86 1.9× 114 3.4× 17 0.5× 16 276
James M. Nichols United States 6 194 1.5× 13 0.2× 40 0.9× 40 1.2× 13 0.4× 15 302
Hans-Jürgen Kühn Germany 10 60 0.5× 60 0.7× 27 0.6× 13 0.4× 15 0.5× 15 361
Kate Lansdell United Kingdom 8 16 0.1× 85 1.0× 82 1.8× 18 0.5× 42 1.3× 9 416
M. Ömer Bostanci Türkiye 12 15 0.1× 33 0.4× 105 2.3× 70 2.1× 34 1.0× 23 325
Sílvia Q. Savergnini Brazil 6 58 0.5× 29 0.4× 36 0.8× 9 0.3× 6 0.2× 7 181
Chris Dvergsten United States 5 113 0.9× 28 0.3× 22 0.5× 85 2.5× 38 1.2× 8 302

Countries citing papers authored by Farhad Sahebkar

Since Specialization
Citations

This map shows the geographic impact of Farhad Sahebkar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Farhad Sahebkar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Farhad Sahebkar more than expected).

Fields of papers citing papers by Farhad Sahebkar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Farhad Sahebkar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Farhad Sahebkar. The network helps show where Farhad Sahebkar may publish in the future.

Co-authorship network of co-authors of Farhad Sahebkar

This figure shows the co-authorship network connecting the top 25 collaborators of Farhad Sahebkar. A scholar is included among the top collaborators of Farhad Sahebkar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Farhad Sahebkar. Farhad Sahebkar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Weinstock, Arie, E. Martina Bebin, Daniel Checketts, et al.. (2024). Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program. Epilepsia Open. 9(5). 1816–1825. 3 indexed citations
2.
3.
Flamini, Robert, Anne M. Comi, E. Martina Bebin, et al.. (2023). Efficacy of cannabidiol in convulsive and nonconvulsive seizure types associated with treatment‐resistant epilepsies in the Expanded Access Program. Epilepsia. 64(8). e156–e163. 13 indexed citations
4.
Thiele, Elizabeth A., Francis Filloux, Floor E. Jansen, et al.. (2023). Long-term Safety and Efficacy of Add-on Cannabidiol (CBD) for Seizures Associated With Tuberous Sclerosis Complex (TSC): 3-Year Results From GWPCARE6 Open-Label Extension (OLE) (P14-1.004). Neurology. 100(17_supplement_2). 2 indexed citations
5.
6.
Szaflarski, Jerzy P., Orrin Devinsky, Yong D. Park, et al.. (2022). Long‐term efficacy and safety of cannabidiol in patients with treatment‐resistant epilepsies: Four‐year results from the expanded access program. Epilepsia. 64(3). 619–629. 21 indexed citations
7.
Thiele, Elizabeth A., E. Martina Bebin, Francis Filloux, et al.. (2021). Long‐term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open‐label extension trial. Epilepsia. 63(2). 426–439. 56 indexed citations
8.
9.
10.
Weinstock, Arie, Daniel Checketts, Gary Clark, et al.. (2021). Long-term Efficacy and Safety of Cannabidiol (CBD) in Patients with Tuberous Sclerosis Complex (TSC): 4-year Results from the Expanded Access Program (EAP) (2405). Neurology. 96(15_supplement). 6 indexed citations
11.
12.
13.
Tayo, Bola, Lesley Taylor, Farhad Sahebkar, & Gilmour Morrison. (2019). A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment. Clinical Pharmacokinetics. 59(6). 747–755. 46 indexed citations
14.
Gologorsky, Rebecca C., Jerome Barakos, & Farhad Sahebkar. (2013). Rhomb- and Bickerstaff Encephalitis: Two Clinical Phenotypes?. Pediatric Neurology. 48(3). 244–248. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marta Żołnowska Breakdown of academic impact, for papers by Richard J. Huntsman Breakdown of academic impact, for papers by Chloe Verducci Breakdown of academic impact, for papers by Henry Blanton Breakdown of academic impact, for papers by James M. Nichols Breakdown of academic impact, for papers by Hans-Jürgen Kühn Breakdown of academic impact, for papers by Kate Lansdell Breakdown of academic impact, for papers by M. Ömer Bostanci Breakdown of academic impact, for papers by Sílvia Q. Savergnini Breakdown of academic impact, for papers by Chris Dvergsten
Rankless by CCL
2026